SCHEMBL3518009

SCHEMBL3518009

O=c1ccc2ccc(S(OS(=O)(=O)c3ccccc3)(c3ccccc3)c3ccccc3)cc2o1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.63
CA12 O43570 9/20 0.44
CA9 Q16790 8/20 0.44
CA1 P00915 7/20 0.44
CA4 P22748 5/20 0.44
CA7 P43166 5/20 0.44
CA2 P00918 4/20 0.44
CA3 P07451 4/20 0.44
CA14 Q9ULX7 4/20 0.44
CA5A P35218 4/20 0.44
CA5B Q9Y2D0 3/20 0.44
CA6 P23280 3/20 0.44
KMT2A Q03164 3/20 0.44
MTNR1A P48039 2/20 0.44
MEN1 O00255 2/20 0.44
NPC1 O15118 1/20 0.44
MAOA P21397 1/20 0.44
MCL1 Q07820 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3519399 0.94 MAOB (0.56) MAOBCA12CA9CA1CA4
SCHEMBL3517310 0.94 MAOB (0.56) MAOBCA12CA9CA1CA4
SCHEMBL3524354 0.91 MAOB (0.53) MAOBCA12CA9CA1CA4
SCHEMBL3523373 0.88 CA12 (0.58) MAOBCA12CA9CA1CA4
SCHEMBL3519709 0.87 MAOB (0.52) MAOBCA12CA9CA1CA4
SCHEMBL3525107 0.87 MAOB (0.49) MAOBCA12CA9CA1CA4
SCHEMBL3521815 0.85 MAOB (0.52) MAOBCA12CA9CA1CA4
SCHEMBL3520432 0.85 MAOB (0.47) MAOBCA12CA9CA1CA4
SCHEMBL3521367 0.84 MAOB (0.48) MAOBCA12CA9CA1CA4
SCHEMBL3520943 0.81 MAOB (0.52) MAOBCA12CA9CA1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7833691-B2 Heterocycle-bearing onium salts WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-11-16 US disclosed
EP-1481973-B1 HETEROCYCLE-BEARING ONIUM SALTS WAKO PURE CHEM IND LTD (JP) 2008-12-31 EP disclosed
EP-1953149-A2 A heterocycle-containing onium salt Wako Pure Chemical Industries, Ltd. (JP) 2008-08-06 EP disclosed
US-20080161520-A1 Heterocycle-bearing onium salts WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-07-03 US disclosed
US-7318991-B2 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2008-01-15 US disclosed
US-20050233253-A1 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether WAKO PURE CHEMICAL INDUSTRIES, LTD (JP) 2005-10-20 US disclosed
EP-1481973-A1 HETEROCYCLE-BEARING ONIUM SALTS Wako Pure Chemical Industries, Ltd. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233253-A1 Diphenylsulfonium compounds in which the S atom is additionally attached to a xanthene-9-onyl-2-yl- or coumarin-7-yl- ring; acid generator for a chemically amplified resist; photopolymerization initiator for polymerizing an epoxide or a vinyl ether NOX4, CBR1, CBR3 MAOB 1286/4885CA12 3023/4885CA9 704/4885
US-20080161520-A1 Heterocycle-bearing onium salts MCM5, NIT2, PCNA MAOB 1248/4885CA12 2139/4885CA9 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.